Lucid Capital Markets Rates Adial Pharmaceuticals (ADIL) buy

Lucid Capital Markets reiterates its buy rating on ADIL, setting a $6 price target, a 101.34% upside from the current price.

By TradeTexts Research Desk · Published Jun 15, 2026, 2:01 PM EDT · Updated Jun 16, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Lucid Capital Markets rated Adial Pharmaceuticals, Inc. ($ADIL) "buy" with a $6 price target on June 15, 2026.

Since the rating, $ADIL is down 4.9% after 1 week, down 4.6% after 1 month and up 22.5% to date (from the $2.85 close on Jun 15, 2026).

ADIL Adial Pharmaceuticals, Inc.

$3.49 -41.83% year to date

Daily close · Oct 16, 2026

Key Points

Lucid Capital Markets reiterated its buy rating on ADIL with a price target of $6 on June 15, 2026.
Lucid Capital Markets's $6 price target implies 101.34% upside from Adial Pharmaceuticals, Inc.'s ($ADIL) current $2.98 share price.
ADIL shares are trading around $2.98, with insider buying activity observed in April 2026.
Geode Capital Management and Tower Research Capital increased their holdings in ADIL, while BlackRock slightly reduced its position.

Get $ADIL trade alerts by text

We text you when insiders, Congress or big funds trade $ADIL. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Adial Pharmaceuticals, Inc. alert may contain errors. Disclosures

Lucid Capital Markets reaffirmed its positive outlook on ADIL by maintaining a buy rating and setting a price target of $6. This update came on June 15, 2026, from analyst Elemer Piros. Shares of ADIL are currently trading around $2.98.

Other Institutional Activity in ADIL

Geode Capital Management significantly increased its holdings in ADIL, adding 18,019 shares to bring its total to 24,249 shares, valued at approximately $43,405. Tower Research Capital also boosted its stake, adding 1,302 shares for a total of 1,356 shares worth about $2,427. Meanwhile, BlackRock slightly trimmed its position by 1 share, now holding 1,110 shares valued at $1,987.

Insider Buying and Selling at Adial Pharmaceuticals, Inc.

Several insiders at ADIL made notable purchases on April 7, 2026. CEO Claiborne Cary acquired 37,985 shares, and CFO Vinay Shah bought 17,325 shares. COO Tony Goodman also purchased 26,510 shares. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

On June 15, 2026, Lucid Capital Markets reiterated its buy rating on ADIL with a $6 price target. Previously, Maxim Group upgraded ADIL to a buy with a $1.5 target on September 30, 2025, and Rodman & Renshaw initiated coverage with a buy rating and an $8 target on November 14, 2024.

Bottom Line

Lucid Capital Markets' reaffirmation of its buy rating for ADIL, along with a $6 price target, underscores continued confidence in the company's potential. Investors are keeping an eye on institutional moves and insider activities as indicators of the stock's future performance. Remember, 13F filings and analyst ratings reflect past actions and may not indicate current positions.

12-month forecast